CLINICAL HANDBOOK OF SCHIZOPHRENIA

632 IndexAmerican CorrectionalAssociation, mental healthstandards for correctionalfacilities, 356American Medical Association,mental health standards forcorrectional facilities, 356American Psychiatric AssociationECT recommendations of, 196–197, 197tmental health standards forcorrectional facilities, 356American Public HealthAssociation, mental healthstandards for correctionalfacilities, 356Americans with Disabilities Act,312housing discrimination and,289Amisulpride, 30, 32Amphetamines, impact onschizophrenia symptoms, 464Amygdala, 48Amygdala–hippocampal complex,48Angerassessing, 401working with, 406–407See also Aggression/violenceAnger hierarchies, 406–407Angina, comorbid, 432Anhedonia, 88, 563Anomalous experiences, 78Anticholinergic effects,antipsychotic-induced, 169tAntidepressantssexual dysfunction and, 606studies of, 191–192Antiepileptic agents. See Moodstabilizers; specific agentsAntihypertensive agents, 430Antipsychotics, 96, 159–167age-related dosing of, 393aggression/violence and, 403–404arrhythmias and, 432atypical, 31–32, 161–164, 163–164, 165tfor African Americans, 621for COS/EOS, 486–487cost-effectiveness of, 511monitoring, 174, 174t, 433–434, 434tmovement disorders and,392, 395during pregnancy, 476reduced side effects of, 168See also Clozapineclassification of, 161–166for COS/EOS, 485–488costs of, 508–509, 508tdecision making about, 161discontinuation of, 168–169and dual diagnosis ofschizophrenia and ID, 442–443efficacy and safety benefits of,168–169ethnic differences inmetabolism of, 620–621for first-episode psychosis,371–372first-generation, 162–163during breast feeding, 475dosing of, 163tduring pregnancy, 474–475gender and, 578–579health risks of, 433–434history of, 29–30impact on substance use, 466for inmates with schizophrenia,361interactions of, 165–166key points, 166–167for late-life schizophrenia, 392–395maintenance and, 160–161mechanism of action of, 29–32metabolism of, 166tnew, cost-effectiveness of, 511–512overdosage of, 176in PACE model, 387pharmacological parameters of,163t, 165, 165tplasma concentrations inchildren/adolescents, 488during pregnancyadvantages/disadvantages/metabolic change, 475tdosing strategies, 476–477second-generation. SeeAntipsychotics, atypicalsexual dysfunction and, 606side effects, 168–177cardiac, 175–176hematological, 176hypothalamic- and pituitaryrelated,171–172key points, 176metabolic, 172–175neurological, 169–171stabilization and, 160STEPS decision model and, 161symptom improvement and,159–160, 160t, 161tthird-generation, 32, 164–165,165ttreatment goals, 159–161treatment recommendations,166typical, 30–31, 161–163, 163t“Antisuicidal” medications, 499–500Antonovsky’s Sense of Coherence,586Anxietycoping strategies for, 274tPACE approach to, 386quality of life and, 587remission in, versus remissionin schizophrenia, 562suicide risk and, 494ttreatment of, 149tAnxiety disorders, 78, 192Apathycharacteristics of, 208and problems with dressing,209tAPIC model of jail diversion,528–529, 528tAripiprazole, 7, 30, 32classification of, 164metabolism of, 166tduring pregnancy, advantages/disadvantages/metabolicchange, 475tside effect potential of, 169ttreatment with, 164–165, 165tweight gain and, 172Arrhythmias, comorbid, 432Asenapine, 32Asking for Support Module, 283,285Asociality, 88Aspartate, 8Assertive community treatment,295, 310, 329–338case management and, 314–314contraindications, 332–333cost-effectiveness of, 512description, 330–333evidence supporting, 333–334evidence-based, 543for first-episode psychosis,373forensic, 363homelessness and, 416–417implementing, 332key points, 337negative outcomes, 333–334for older adults, 393–394for parents, 478practice recommendations,334–337step-down, 333target population, 332versus traditional services,329